Fredun Pharmaceuticals Share Price

Small Cap | Pharmaceuticals and health care | BSE: 539730

₹678.05 image3.15 (0.47 %)

Last Updated: 13 Mar 2025 12:00 AM

Technicalsimage BEARISHimage

Overview

Open (₹) 685.00

High (₹) 685.00

Low (₹) 673.25

Prev. Close (₹) 674.90

Volume 5,711

VWAP (₹) 680.33

ROCE (%) 24.93

Industry P/E 43.95

TTM P/E 17.03

P/B Ratio 2.62

Market Cap (₹) Cr.320.15

Dividend Yield (%)0.10

EPS (₹) 33.32

ROE12.89%

Sales Growth (%) 26.75

Profit Growth (%)44.57

Day Range

685.00685.00

L
H

52 Week Range

635.001,024.00

L
H

Historical Returns

Returns (6M)

-14.52 %

Returns (1Y)

-6.63 %

Returns (3Y)

-30.72 %

Returns (5Y)

497.4 %

Returns (6M)

-14.52 %

Returns (1Y)

-6.63 %

Returns (3Y)

-30.72 %

Returns (5Y)

497.4 %

SWOT Analysis

  • Growth in Net Profit Margin (QoQ)

Technicals
info_icon

Technical Rating

Trendimage  BEARISH
Moving Averages
Technical Indicators
Bullish
Bullish

RSI 36.35

MFI 29.39

ATR 30.49

Commodity Channel Index -70.34

ROC125 -13.52

ROC21 3.61

Williams %R -71.73

Resistance & Support
info_icon

TypeResistance 1 Resistance 2 Resistance 3 PP Support 1 Support 2 Support 3
Current683.00685.50687.00681.50679.00677.50675.00
Week Ago693.24704.62711.24686.62675.24668.62657.24
Month Ago684.84699.42711.84672.42657.84645.42630.84

EMA & SMA
info_icon

678.05

Current Price

EMA & SMApin

Bullish Moving Averages

0

Bearish Moving Averages

20

5 Day 683.30


9 Day 684.31


10 Day 685.62


12 Day 698.47


14 Day 701.58

20 Day 699.57


26 Day 697.04


50 Day 707.27


100 Day 723.41


200 Day 773.26

Deals & Announcements

Bulk and Block Deals

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
ASHOK JHINGANbulkSell14 Sept, 2021₹443.0724,000BSE
ANAND JHINGANbulkSell14 Sept, 2021₹422.4824,758BSE
ZAHEER .bulkSell01 Jul, 2020₹183.281,12,025BSE
SURINDER GURMUKH DHAULbulkSell01 Jul, 2020₹186.1924,881BSE
KAMAL KUMAR JALAN SEC. PVT. LTDbulkSell01 Jul, 2020₹187.3033,697BSE
ZAHEER .bulkBuy01 Jul, 2020₹186.011,12,025BSE
SURINDER GURMUKH DHAULbulkBuy01 Jul, 2020₹183.4824,881BSE
KAMAL KUMAR JALAN SEC. PVT. LTDbulkBuy01 Jul, 2020₹184.8333,872BSE

Insider Trading

DateNameActionAvg. PriceQuantityDeal Value
22 Sept, 2023Fredun MedhoraAcquisition₹996.2019,072BSE
25 Aug, 2023DAULAT MEDHORAAcquisition₹996.2018,068BSE
18 Oct, 2022Fredun MedhoraAcquisition₹996.2019,072BSE
18 Oct, 2022Daulat MedhoraAcquisition₹996.2018,068BSE
25 Nov, 2021Nariman MedhoraAcquisition₹422.101,44,515BSE
25 Nov, 2021Daulat MedhoraAcquisition₹422.1052,120BSE
22 Nov, 2021Daulat MedhoraAcquisition₹421.3752,210BSE
22 Nov, 2021Nariman MedhoraAcquisition₹422.101,44,515BSE

Corporate Actions

Announcement DateSubjectEx - DateRecord Date
08 May, 2024Rs.0.7000 per share(7%)Final Dividend23 Sept, 202423 Sept, 2024
25 May, 2023Rs.0.7000 per share(7%)Final Dividend22 Sept, 202322 Sept, 2023
16 May, 2022Rs.0.7000 per share(7%)Final Dividend01 Jan, 197001 Jan, 1970

Announcements

DateSourceDetail
11 Mar, 2025BSE IndiaTHE COMPANY ANNOUNCES ITS FORAY INTO THE LARGE ANIMAL VETERINARY SEGMENT BY PROVIDING INNOVATIVE SOLUTIONS FOR LARGE ANIMAL HEALTH TO ADDRESS THEIR KEY HEALTH CHALLENGES.
24 Feb, 2025BSE IndiaWe wish to inform you that based on the recommendation of the Audit Committee, the Board of Directors of the Company has at its meeting held today i.e. on February 24, 2025, has approved the appointment of Nikhil Maniar & Associates., Chartered Accountants (Firm Reg. No. 128056W) as the Internal Auditor of the Company for the Financial year 2024-2025.
24 Feb, 2025BSE IndiaWe wish to inform you that based on the recommendation of the Audit Committee, the Board of Directors of the Company has at its meeting held today i.e. on February 24, 2025, has approved the appointment of Nikhil Maniar & Associates., Chartered Accountants (Firm Reg. No. 128056W) as the Internal Auditor of the Company for the Financial Year 2024-2025.
19 Feb, 2025BSE IndiaIntimation under Regulation 30 of SEBI (LODR) Regulations, 2015-Resignation of Company Secretary and Compliance Officer.
04 Feb, 2025BSE IndiaFredun Pharmaceuticals Reports Exceptional Q3 and 9M FY25 Performance
04 Feb, 2025BSE IndiaUnaudited Financial Results for the quarter and nine months ended 31.12.2024 along with Integrated Filing (Financial).
04 Feb, 2025BSE IndiaUnaudited Financial Results for the quarter and nine months ended 31.12.2024
04 Feb, 2025BSE IndiaPursuant to Regulation 30 and 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Tuesday, February 04, 2025 has inter-alia, considered, adopted and approved following items of business: 1. In compliance to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015, the Un-Audited Financial Results of the Company for the Quarter Ended 31st December, 2024 along with the Limited Review Report as issued by M/s. R.H. Nisar & Co, Statutory Auditors of the Company; copies of which are attached hereunder; 2.Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held today has ratified incorporation of a Wholly Owned Subsidiary ('WOS') with the name as Fredun Retail Private Limited as approved by the Ministry of Corporate Affairs, Government of India.
03 Feb, 2025BSE IndiaFredun Pharmaceuticals Enhances Production Capacities with it''s Second Italian Tube Filling Machine, Boosting Capacity by 2.9x.
22 Jan, 2025BSE IndiaFredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2025 ,inter alia, to consider and approve Prior Intimation for the Board Meeting of the Company to be held on Tuesday, 04th February, 2025.

Board Meetings

PurposeDetailsMeeting DateBroadcast Date
Quarterly Results--23 Jan, 202504 Feb, 2025
Quarterly Results--16 Oct, 202426 Oct, 2024
Othersinter alia consider issue and allotment of Unsecured Foreign Currency ConvertibleBonds (FCCBs), in accordance with the provisions of the SEBI Regulations, 2018 and the Companies Act, 2013.28 Sept, 202403 Oct, 2024
Quarterly Results--23 Jul, 202429 Jul, 2024
Audited Results & Final Dividend--25 Apr, 202407 May, 2024
Quarterly Results--06 Feb, 202414 Feb, 2024
OthersInter alia, to consider a proposal for fund raising up to Rs.120 crores by way of further public offer, rights issue, debt issue, preferential issue or any other method.11 Dec, 202316 Dec, 2023
Quarterly Results--02 Nov, 202308 Nov, 2023
Quarterly Results--12 Jul, 202319 Jul, 2023
Audited Results & Final Dividend--19 May, 202324 May, 2023

Share Holding Pattern

Loading...

Loading...

Owner NameDec, 2024Sept, 2024Jun, 2024Apr, 2024Mar, 2024Dec, 2023

About Fredun Pharmaceuticals

Fredun Pharmaceuticals is a Public Limited Listed company incorporated on 08/06/1987 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1987PLC043662 and registration number is 043662. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 348.16 Cr. and Equity Capital is Rs. 4.70 Cr. for the Year ended 31/03/2024. Read More

Parent Organisation

Not Applicable

Founded

1987

Managing Director

Mr. Fredun Medhora

NSE Symbol

--

Fredun Pharmaceuticals Management

NameDesignation
Dr.(Mrs.) Daulat N MedhoraChairman & Jt. M. D
Mr. Fredun MedhoraManaging Director & CFO
Mr. Nariman MedhoraNon Executive Director
Dr. Rohinton KangaInd. Non-Executive Director
Dr. Aspi RaimalwalaInd. Non-Executive Director
Mrs. Daisy D’souzaInd. Non-Executive Director

Peer Comparison

StocksMarket CapMarket Price52 Week Low-High
Sun Pharmaceutical Industries₹4,03,916.05₹1,683.45 image
₹1,676.85(0.39%)
₹1,376.750 - ₹1,960.200
Divi's Laboratories₹1,49,205.29₹5,620.45 image
₹5,667.15(-0.82%)
₹3,350.050 - ₹6,448.750
Cipla₹1,18,065.23₹1,461.90 image
₹1,454.30(0.52%)
₹1,317.600 - ₹1,702.000
Torrent Pharmaceuticals₹1,03,430.62₹3,056.05 image
₹3,096.50(-1.31%)
₹2,488.000 - ₹3,589.950
Dr. Reddy's Laboratories₹92,453.48₹1,107.95 image
₹1,105.15(0.25%)
₹1,093.000 - ₹1,420.200

FAQs on Fredun Pharmaceuticals

What is the share price of Fredun Pharmaceuticals?

The share price of Fredun Pharmaceuticals on 13 Mar, 2025 is ₹ 678.05.

What is 52W high and 52W low share price of Fredun Pharmaceuticals?

The highest and lowest 52W share prices of Fredun Pharmaceuticals are ₹ 1024.000 and ₹ 635.000

What is the market cap of Fredun Pharmaceuticals?

The market capitalization of Fredun Pharmaceuticals as of 13 Mar, 2025 is ₹ 320.15 Crores

What is the P/E ratio of Fredun Pharmaceuticals?

The current P/E ratio of Fredun Pharmaceuticals as of 13 Mar, 2025 is 43.95

What is the PB ratio of Fredun Pharmaceuticals?

The PB ratio of Fredun Pharmaceuticals as of 13 Mar, 2025 is 2.62

Top Gainers

₹6.97image

₹5.81 (0.20%)

₹194.70image

₹162.25 (0.20%)

Top Losers

₹13.75image

₹135.15 (-0.90%)

₹9.60image

₹12.00 (-0.20%)

₹9.80image

₹93.55 (-0.90%)

₹0.99image

₹4.77 (-0.79%)

Market Indices

Sensex

₹73,828.91image

₹74,029.76 (0.00%)

Source : Dion Global Solutions Limited